Light-activated treatment for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new treatment that uses light to activate a drug attached to cancer cells, aiming to destroy them during surgery. It is for people with pancreatic cancer that has not spread and who have already had chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has not spread to other parts of the body
- You have completed chemotherapy before this treatment
- You are scheduled for surgery to remove the tumor
- You are 18 years or older
- You are generally able to care for yourself (ECOG score 0-1)
- Your blood counts and liver/kidney function are within acceptable levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.